$LIPO News

Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing

Lipella Pharmaceuticals Announces Positive Final Results from Phase 2a Study of LP-10 in Oral Lichen Planus

Lipella Pharmaceuticals to Present at Zacks SCR Life Sciences Virtual Investor Forum and Report Final Phase 2a Results in Oral Lichen Planus

Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting

Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market

Lipella Pharmaceuticals Announces Delisting From Nasdaq Capital Market

Lipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic Technology

Lipella Pharmaceuticals Granted U.S. Patent For MRI-Based Detection Method For Interstitial Cystitis, Titled "Systems And Methods Of Detecting Interstitial Cystitis" Extending Protection Through 2045

Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development

Lipella Pharmaceuticals Re-Signs Manufacturing Collaboration Agreement With Cook MyoSite For LP-310 Clinical Development

Lipella Pharmaceuticals to Present Phase 2a Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International Meeting

Lipella Pharma To Present Topline Data From First Two Dose Cohorts Of Ongoing Phase 2A Trial Of LP-310 For Treatment Of OLP At 2025 Joint International Meeting Of AAOM And EAOM In Las Vegas

Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on “Global Transformation in Oral Medicine”

Lipella Pharmaceuticals To Present Abstract On Oral Lichen Planus Treatment At 2025 AAOM/EAOM International Meeting Conference On "Global Transformation in Oral Medicine"

Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025

Lipella Posts Productive Results From The Second Cohort Of Trial Evaluating LP-310 For The Treatment Of Oral Lichen Planus; Expects Final Results In Q2 FY25

Lipella enrols all subjects in Phase IIa trial targeting oral lichen planus

Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus

Lipella Pharmaceuticals Completes Enrollment In Phase 2a Trial Of LP-310 Liposomal Tacrolimus Oral Rinse For The Treatment Of Oral Lichen Planus (OLP)

Lipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse Podcast